- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about VTRS
Recent news which mentions VTRS
From Benzinga
Why Viatris Stock Dropped 24% in February
March 08, 2022
From Motley Fool
3 New Reasons to Sell Viatris Stock Right Now
March 07, 2022
From Motley Fool
From Motley Fool
Want to Be a Contrarian Investor? Buy Viatris Stock Now
March 04, 2022
From Motley Fool
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
Consumer Spending, E-Commerce, and the Business of Lodging
March 02, 2022
From Motley Fool
From Benzinga
67 Biggest Movers From Yesterday
March 01, 2022
From Benzinga
Why Viatris Shares Are Trading Lower Today
February 28, 2022
From Benzinga
Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver
February 28, 2022
From MarketWatch
Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters
February 28, 2022
From Benzinga
Here's Why Viatris Stock Is Sliding on Monday
February 28, 2022
From Motley Fool
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
From Benzinga
Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict
February 28, 2022
From Benzinga
India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal
February 28, 2022
Tickers
VTRS
From Benzinga
3 Dirt-Cheap Dividend Stocks to Buy in March
February 28, 2022
From Motley Fool
Earnings Scheduled For February 28, 2022
February 28, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
3 Charts That Show Just How Ridiculously Massive Pfizer's COVID-19 Revenue Will Be in 2022
February 18, 2022
From Motley Fool
Here's My Top Value Stock to Buy Right Now
February 07, 2022
From Motley Fool
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
2 Reasons To Buy Viatris Stock, and 1 Reason to Sell
February 05, 2022
From Motley Fool
This way of picking value stocks has actually worked — and Berkshire Hathaway screens the best
February 04, 2022
From MarketWatch
Is Viatris a Value Trap?
February 01, 2022
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.